Table 1 Univariate and multivariate analysis of variables associated with incomplete cytoreduction at interval debulking surgery
| Â | Total (93Pts.) | R0 (65Pts.) | Non-R0 (28 Pts.) | Uni-variate p value | Multi-variate p value |
|---|---|---|---|---|---|
Age, years | Â | Â | Â | Â | Â |
 Median (range) | 60 (36–82) | 59,5 (36–82) | 65,7 (47–82) | NS |  |
 Age ≥ 60 | 54 (58%) | 32 (49,2%) | 22 (78,6%) | 0.011 | 0.007 |
FIGO stage | Â | Â | Â | Â | Â |
 IIIA | 9 (9,7%) | 6 (9,2%) | 3 (10,7%) |  |  |
 IIIB | 14 (15%) | 9 (13,8%) | 5 (17,9%) | NS |  |
 IIIC | 58 (62,4%) | 43 (66,2%) | 15 (53,5%) |  |  |
 IV | 12 (12,9%) | 7 (10,8%) | 5 (17,9%) |  |  |
Histology | Â | Â | Â | Â | Â |
 High-grade serous | 81(87%) | 57 (87,6%) | 24 (85,7%) |  |  |
 Endometroid | 4 (4,3%) | 2 (3,1%) | 2(7,1%) | NS |  |
 Mucinous | 2 (2,2%) | 1 (1,5%) | 1 (3,6%) |  |  |
 Clear cell | 2 (2,2%) | 2 (3,1%) | 0 |  |  |
 Other/non specified | 4 (4,3%) | 3 (4,6%) | 1 (3,6%) |  |  |
ECOG Performance Status | Â | Â | Â | Â | Â |
 0 | 34 (37%) | 26 (40%) | 8 (29,6%) | NS |  |
 1 | 44 (47,8%) | 30 (46,2%) | 14 (51,9%) |  |  |
 2 | 15 (15,2%) | 9 (13,8%) | 6 (21,4%) |  |  |
Ca 125 values, UI/dl | Â | Â | Â | Â | Â |
 Median CA-125 at diagnosis (range) | 2121 (10454–28) | 1964 | 2793 | NS | NS |
 CA-125 at diagnosis > 550 | 71 (76,3%) | 46 (70,8%) | 25 (89,3%) | 0.044 | 0.014 |
 Median CA-125 post NACT (range) | 342 (2620–7) | 163 | 598 | 0.055 | NS |
 Ca 125 post NACT > 33 | 60 (65,9%) | 35 (55,6%) | 25 (89,3%) | 0.002 | NS |
 CA 125 reduction post NACT < 96% | 34 (38,2%) | 26 (41,9%) | 8 (29,6%) | 0.034 | NS |
Chronic Disease Score (CDS) | Â | Â | Â | Â | Â |
 1 | 61 (65,6%) | 44 (67,7%) | 17 (60,7%) |  |  |
 2 | 24 (25,8%) | 17 (26,2%) | 7 (25%) | NS |  |
 3 | 8 (8,6%) | 4 (6,2%) | 4 (14,3%) |  |  |
Peritoneal Cancer Index | Â | Â | Â | Â | Â |
 0–16 | 68 (73,1%) | 58 (85,3%) | 10 (35,8%) | < 0.001 | < 0.001 |
 > 16 | 25 (26,9%) | 7 (10,7%) | 18 (64,2%) | ||
Chemotherapy regimen | Â | Â | Â | Â | Â |
 - Carboplatin plus paclitaxel | 81 (87,3%) | 57 (87,6%) | 24 (85,7%) | NS |  |
 - Single agent carboplatin | 3 (3,2%) | 2 (3,1%) | 1 (3,6%) | ||
 - Carboplatin plus PLD | 2(2,2%) | 2 (3,1%) | 0 | ||
 - Carboplatin plus paclitaxel plus bevacizumab | 7 (7,6%) | 4 (6,2%) | 3 (10,7%) |